(Q38465633)

3 September 2017

title

Public health impact of statin prescribing strategies based on JUPITER. (English)

1 reference

3 September 2017

0 references

6

Gérard Waeber

1 reference

3 September 2017

7

Peter Vollenweider

1 reference

3 September 2017

3

Jacques Cornuz

1 reference

3 September 2017

5

Fred Paccaud

1 reference

3 September 2017

David Nanchen

1

1 reference

3 September 2017

Mark J Pletcher

series ordinal

2

1 reference

3 September 2017

Pedro-Manuel Marques-Vidal

series ordinal

4

1 reference

3 September 2017

Nicolas Rodondi

series ordinal

8

1 reference

3 September 2017

language of work or name

English

0 references

publication date

3 December 2010

1 reference

3 September 2017

1 reference

3 September 2017

volume

52

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

159-163

1 reference

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Expanding the orbit of primary prevention--moving beyond JUPITER.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

The "number needed to treat" turns 20--and continues to be used and misused

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Randomized trials stopped early for benefit: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2010.11.018

10.1016/J.YPMED.2010.11.018

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference